Clinical Trial Update: A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder [Phase 1]

View source ↗

Summary

Phase 1 study evaluating RO4917838 on biomarker measures of cognitive dysfunction in participants with schizophrenia and schizoaffective disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• RO4917838

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED